Webinar series uHTS Mass Spectrometry in Drug Discovery

This webinar took place on May 27, 2017

Webinar series part 1: Changes and Challenges in Early Drug Discovery Today

Success or failure in drug development goes back to the early stages of drug discovery. In a series of webinars conducted together with the Division of Pharmacy Professional Development at the University of Wisconsin, we would like to discuss with you todays challenges, oppurtunities and state-of-the art technologies in early drug discovery. In the first installment of the series, W. Adam Hill will give an insight into the challenges and limitations researchers are facing in early drug discovery.

Webinar series part 2: High-throughput MALDI TOF Mass Spectrometry for Drug Discovery in the Ubiquitin System

In this webinar Matthias Trost shows how the drug discovery process can be accelerated beyond conventional technologies with advanced mass spectrometry technology.

Webinar series part 3: Advancements in MALDI-TOF Mass Spectrometry towards Ultra High Throughput Screening

In this webinar of the Bruker-DPPD webinar series, Melanie Leveridge will discuss how the MALDI-TOF works in a real life pharmaceutical application. Real pharma examples and application vignettes are presented by a pharmaceutical Company Researcher (e.g. GSK) using automated MALDI-TOF to push back the boundaries and limits of conventional methods. This should be the message which validates the arguments and assertions made earlier.


Melanie Leveridge

Head, Screening Profiling and Mechanistic Biology, UK at GSK

Melanie graduated from the University of Bristol, UK with first class honours in Biology, and  joined GSK in 2005. She has  since held  roles of increasing responsibility in high throughput screening, compound profiling and assay development, predominantly in support of  respiratory, neuroscience  and immunoinflammation therapy areas. Melanie  has particular expertise in the application of high throughput mass spectrometry techniques for screening and compound profiling. In her current role as Director of  Screening, Profiling and Mechanistic Biology, at the GSK Medicines Research Centre in Stevenage UK,  Melanie leads a department of  50 scientists who partner with therapy area units to select the best targets for small molecule drug discovery approaches. Her team develop and prosecute assays and mechanistic biology studies to understand target:molecule interactions using a range of biochemical, biophysical , cellular and phenotypic assay approaches.

Matthias Trost

Professor of Proteomics at Newcastle University

Matthias studied chemistry in Freiburg, Germany and Manchester, UK. He has a PhD in Cellular Microbiology & Proteomics from the Helmholtz Centre for Infection Research, Braunschweig, Germany and was a postdoctoral fellow with Michel Desjardins at the University of Montreal, Canada and with Pierre Thibault, Institute for Research in Immunology and Cancer, Montreal, Canada. In 2010 he became Programme Leader and Head of Proteomics at the MRC Protein Phosphorylation Unit at the University of Dundee, UK. Since 2016, he is Professor of Proteomics at Newcastle University. Matthias’s research focusses on large-scale proteome and PTM analyses to understand innate immunity in macrophages. He also has a strong interest in drug discovery for which his lab developed high-throughput MALDI TOF mass spectrometry.

Adam Hill

CTO at Triple Sharp Venture Engineering


For Research Use Only. Not for use in clinical diagnostic procedures.